Background: No data regarding subcutaneous-implantable cardioverter defibrillator (S-ICD) technology in patients actively engaging in sports activities are available. Objective: This study aims to compare S-ICD performance between athletes and nonathletes. Methods: The primary outcome of the study was the comparison of overall device-related complications between athletes and nonathletes. Appropriate shocks, inappropriate shocks, and individual device-related complications were secondary outcomes. Results: A total of 1493 patients were extracted from the International Subcutaneous Implantable Cardioverter Defibrillator Registry (iSUSI) registry, of whom 152 (10.2%) were athletes, mostly engaging in dynamic sports (54.2%). Brugada syndrome, myocarditis, and arrhythmogenic right ventricular cardiomyopathy (ARVC) were more common in athletes (11.2% vs 3.3%, P <.001; 19.1% vs 9.0%, P <.001; 8.6% vs 2.8%, P <.001, respectively). During a median follow-up time of 25.5 (12.0–41.2) months, athletes were more likely to experience appropriate shocks (yearly rate: 7.2 [4.9–10.7] % vs 4.3 [3.6–5.1] %, P =.028), occurring more frequently during exercise (3.9% vs 0.6%, P <.001). This finding lost significance when adjusting for confounders (adjusted hazard ratio [aHR] 1.440 [0.909–2.281], P =.120). No differences were found in overall device-related complications (yearly rate: 3.3% vs 3.4%, P =.448) and inappropriate shocks (yearly rate: 5.3% vs 3.7%, P = 0.111). Myopotential oversensing (4.0% vs 1.3%, P =.011) was more common in athletes, as were lead infections (3.3% vs 0.9%, P =.008), with the latter clustering in the early postimplantation period. Conclusion: The S-ICD is a valid therapeutic option for preventing sudden cardiac death in athletes. Sports practice was not associated with an increased risk of complications or inappropriate shocks, although athletes are exposed to a higher risk of S-ICD infections in the early postoperative period.
Long-term performance of subcutaneous implantable defibrillators in athletes: A multicenter, real-world analysis of sport activities from the iSUSI registry / A. Gasperetti, M. Schiavone, J. Vogler, P. Compagnucci, M. Laredo, A. Breitenstein, S. Gulletta, M. Martinek, L. Kaiser, C. Lavalle, S. Gaine, L. Santini, A. Dello Russo, P. Palmisano, G. Rovaris, A. Curnis, N. Ventrella, J. Kuschyk, M. Biffi, R. Tilz, L. Di Biase, C. Tondo, G.B. Forleo. - In: HEART RHYTHM. - ISSN 1547-5271. - 22:7(2025 Jul), pp. 1782-1789. [10.1016/j.hrthm.2024.09.039]
Long-term performance of subcutaneous implantable defibrillators in athletes: A multicenter, real-world analysis of sport activities from the iSUSI registry
C. TondoPenultimo
;
2025
Abstract
Background: No data regarding subcutaneous-implantable cardioverter defibrillator (S-ICD) technology in patients actively engaging in sports activities are available. Objective: This study aims to compare S-ICD performance between athletes and nonathletes. Methods: The primary outcome of the study was the comparison of overall device-related complications between athletes and nonathletes. Appropriate shocks, inappropriate shocks, and individual device-related complications were secondary outcomes. Results: A total of 1493 patients were extracted from the International Subcutaneous Implantable Cardioverter Defibrillator Registry (iSUSI) registry, of whom 152 (10.2%) were athletes, mostly engaging in dynamic sports (54.2%). Brugada syndrome, myocarditis, and arrhythmogenic right ventricular cardiomyopathy (ARVC) were more common in athletes (11.2% vs 3.3%, P <.001; 19.1% vs 9.0%, P <.001; 8.6% vs 2.8%, P <.001, respectively). During a median follow-up time of 25.5 (12.0–41.2) months, athletes were more likely to experience appropriate shocks (yearly rate: 7.2 [4.9–10.7] % vs 4.3 [3.6–5.1] %, P =.028), occurring more frequently during exercise (3.9% vs 0.6%, P <.001). This finding lost significance when adjusting for confounders (adjusted hazard ratio [aHR] 1.440 [0.909–2.281], P =.120). No differences were found in overall device-related complications (yearly rate: 3.3% vs 3.4%, P =.448) and inappropriate shocks (yearly rate: 5.3% vs 3.7%, P = 0.111). Myopotential oversensing (4.0% vs 1.3%, P =.011) was more common in athletes, as were lead infections (3.3% vs 0.9%, P =.008), with the latter clustering in the early postimplantation period. Conclusion: The S-ICD is a valid therapeutic option for preventing sudden cardiac death in athletes. Sports practice was not associated with an increased risk of complications or inappropriate shocks, although athletes are exposed to a higher risk of S-ICD infections in the early postoperative period.| File | Dimensione | Formato | |
|---|---|---|---|
|
long term.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
773.7 kB
Formato
Adobe PDF
|
773.7 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




